"Body recomposition" usually means losing fat while preserving or gaining lean mass. GLP-1 and dual GIP/GLP-1 medicines can produce large average weight losses. Exogenous testosterone, in appropriately diagnosed hypogonadism, can increase lean mass and improve some androgen-deficiency symptoms. Using both together is not an FDA-approved indication, and compounding clinics sometimes outrun the evidence.
What it is
- TRT: Prescription testosterone for men with confirmed hypogonadism (symptoms + consistently low testosterone), per Endocrine Society guidance—not a lifestyle enhancer for normal levels.
- GLP-1 pathway medicines: Semaglutide, tirzepatide, and related agents for eligible obesity/overweight care (and other labeled uses), with diet and activity.
- "Stack": Informal term for concurrent use. It is a clinical judgment call when both conditions coexist (e.g., obesity plus documented hypogonadism)—not a DIY protocol.
How it works (plausible physiology vs proof)
GLP-1 / tirzepatide: Reduce energy intake; weight loss includes fat mass and some lean mass on DXA. Labels note greater fat than lean loss, not zero lean loss.
Testosterone in hypogonadism: Can support secondary sex characteristics, libido in deficient men, and lean mass; it also suppresses the HPT axis and spermatogenesis, can raise hematocrit, and requires monitoring (PSA discussions, blood pressure considerations after FDA label updates, etc.).
Why people combine them: Hypogonadism and obesity frequently overlap. Weight loss can raise endogenous testosterone in some men with obesity-related secondary hypogonadism—Endocrine Society commentary often prioritizes weight loss when obesity is the driver. Conversely, untreated severe deficiency may hinder training quality. None of that automatically means every man on a GLP-1 "needs" TRT.
What evidence shows
| Claim | Status |
|---|---|
| GLP-1/GIP agonists produce substantial weight loss vs placebo in obesity RCTs | Established (STEP, SURMOUNT programs) |
| TRT can increase lean mass in men with documented hypogonadism | Established (guideline-supported physiologic effect; individual response varies) |
| TRAVERSE: CV safety of TRT gel in hypogonadal men with CV disease/risk | Established RCT — noninferiority for MACE vs placebo in that trial design (Lincoff et al., 2023); other adverse events still matter |
| Dedicated large RCTs proving TRT + GLP-1 is superior for "recomposition" vs GLP-1 + resistance training + protein alone | Unknown / emerging at best — not a labeled indication |
| Stacking is safe without labs or for eugonadal men seeking aesthetics | Unproven and inconsistent with guidelines |
Honest gap: Much "stack" content online extrapolates from separate literatures. That is hypothesis-generating, not proof.
Risks
Combination therapy means combined monitoring burden:
- TRT: hematocrit/erythrocytosis, fertility suppression, acne/edema, sleep apnea worsening potential, blood pressure increases (FDA class labeling updates), shared decision-making on prostate monitoring
- GLP-1 class: GI effects, gallbladder disease, rare pancreatitis concerns, MTC/MEN2 contraindications, lean-mass decline with rapid weight loss
- Practical risks: under-eating protein, skipping resistance training, dehydration, and attributing all fatigue to "low T" when calorie deficit is the driver
FDA testosterone labeling changes in 2025 reflected TRAVERSE findings (removing certain CV boxed-warning language while adding/emphasizing blood-pressure information)—still not a green light for unsupervised use.
Who should discuss with a clinician
Men over 35 with obesity or overweight plus symptoms and labs consistent with hypogonadism, or men already on one therapy who develop an indication for the other. Especially discuss if you want children soon, have polycythemia, prostate concerns, MTC/MEN2 history, recent major CV events, or uncontrolled sleep apnea.
If weight is the main issue and testosterone is only mildly low once, ask about repeating morning labs and prioritizing nutrition, sleep, and resistance training before adding hormones.
Bottom Line
The "TRT + GLP-1 stack" is a popular phrase for two separately studied tools that sometimes coexist in the same patient. Evidence for intentional stacking as a recomposition protocol is far thinner than evidence for each class alone. Guideline-based diagnosis, resistance training, adequate protein, and lab monitoring matter more than stacking for its own sake.
So what?
Ask a licensed clinician: (1) Do I meet criteria for each therapy independently? (2) What labs and follow-up cadence apply? (3) How will we protect lean mass and fertility goals?
Learn how Scoreboard Health structures men's evaluation pathways with licensed providers on How it works or browse education-oriented options on Treatments.
Related reading
Disclaimer: Not medical advice. Not an instruction to combine medications. Compounded products are not FDA-approved. FDA-approved labels govern approved products.
Medically reviewed by: Ana Argote, BSN, R.N.
Sources
- Bhasin S, et al. Endocrine Society testosterone guideline (2018). PubMed · Society summary
- Endocrine Society. Statement on Testosterone Replacement Therapy (2026). endocrine.org
- Lincoff AM, et al. TRAVERSE. N Engl J Med. 2023. nejm.org
- U.S. FDA. Class-wide labeling changes for testosterone products. fda.gov
- Wilding JPH, et al. STEP 1. N Engl J Med. 2021. nejm.org
- Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022. nejm.org
Learn how Scoreboard Health structures men's evaluation pathways: How it works · Treatments